4.5 Article

Industry White Paper: Contemporary Opportunities and Challenges in Characterizing Crystallinity in Amorphous Solid Dispersions

期刊

JOURNAL OF PHARMACEUTICAL SCIENCES
卷 111, 期 6, 页码 1543-1555

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.xphs.2022.01.007

关键词

Amorphous solid dispersion(s) (ASD); Analysis; Crystallinity; Differential scanning calorimetry (DSC); Infrared (IR) spectroscopy; Near-infrared spectroscopy (NIRS); Raman spectroscopy; Solid-state NMR (SSNMR) spectroscopy; X-ray powder diffraction (XRD)

资金

  1. International Consortium for Innovation and Quality in Pharmaceutical Development

向作者/读者索取更多资源

The IQ Consortium Working Group on Characterization of Amorphous Solid Dispersions shares their perspective on the analytical challenges and limitations of detecting low levels of crystalline drug substance in ASDs and associated drug products. They aim to guide development, support control strategies, and enable registration of quality products using highly sensitive analytical technologies. The article highlights the unique challenges of monitoring crystalline drug substance and emphasizes the merits and limitations of diverse analytical tools.
Members of the IQ Consortium Working Group on Characterization on Amorphous Solid Dispersions shares here a perspective on the analytical challenges, and limitations of detecting low levels of crystalline drug substance in amorphous solid dispersions (ASDs) and associated drug products. These companies aim to employ highly sensitive commercially available analytical technologies to guide development, support control strategies, and enable registration of quality products. We hope to promote consistency in development and registration approaches and guide the industry in development of characterization best practices in the interest of providing high quality products for patients. The first half of this perspective highlights the unique challenges of analytical methodologies to monitor crystalline drug substance in ASDs and their associated drug products. Challenges around use of limit tests, analyte spiking experiments, and method robustness are also underscored. The latter half describes the merits and limitations of the diverse analytical toolbox (such as XRPD, NIR and DSC), which can be readily applied during development and, in some cases, considered for potential application and validation in the commercial QC setting when necessary. (C) 2022 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据